Switching to a two-drug HIV regimen for transgender women
Treatments studied
Part of Infections clinical trials.
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a transgender woman (self-identified).
- You have been on a stable three-drug HIV regimen for at least 3 months with undetectable HIV levels.
- You have had at least two HIV tests showing undetectable levels in the past year.
- You do not have active hepatitis B or C (or untreated syphilis).
- You have no history of resistance to dolutegravir or lamivudine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This study tests an experimental medicine (alimatravir, also called MK-8527) as a way to prevent HIV infection. The trial is designed specifically for transgender and gender diverse people who are on gender-affirming hormone therapy and have a low risk of HIV exposure.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
This trial studies a two-drug pill (DTG/3TC) for people who have never taken HIV medication before. It aims to see if this simpler treatment is effective and safe for controlling HIV-1.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.